A Breast Cancer Test That Saves Lives
|
| Posted
:
Tue, 03 Nov 2009 10:01:28 GMT |
| Author
:
Provista |
| Category
:
Press Release |
| News Alerts by
Email ( click
here ) |
|
|
|
|
The BT Test(R) - A Simple Blood Test for the Early Detection of Breast Cancer PHOENIX, Nov. 3
PHOENIX, Nov. 3 /PRNewswire/ -- A healthy 44-year-old woman will celebrate many future birthdays thanks to the efforts of Dr. Keri Sweeten and a new blood test for breast cancer.
Dr. Sweeten, a board-certified gynecologist and Fellow of the American College of Obstetricians and Gynecologists, recently incorporated the Provista Life Science BT TestĀ®, a blood test for the detection of breast cancer, into her patient care practice. Sweeten noted a case where a 44-year-old patient called to schedule her annual mammogram, and in advance of the mammogram Sweeten ordered the BT Test. When her patient's BT ScoreĀ® came back high, indicating an increased likelihood of the presence of breast cancer, she changed the order for her patient's routine screening mammogram to a diagnostic bilateral mammogram.
A diagnostic mammogram is an enhanced radiology procedure that increases the number and angles of breast imaging views with increased magnification of those views. Using this procedure, the radiologist was able to locate a deep, very small clustering of suspicious looking cells in the patient's left breast. A biopsy was recommended, performed and the subsequent pathologist's report came back with a confirmed diagnosis of cancer. Surgery was scheduled two weeks later and the cancerous growth removed.
"My patient is a young woman with dense breast tissue where the sensitivity of digital and film mammography is known to be limited, but is still considered the standard of care. Had it not been for the BT Test, we might not have caught her cancer," said Sweeten. "My patient's first reply to me was, 'You saved my life.' I'm not sure much more needs to be said."
The BT Test, or the Biomarker Translation Test, is a CLIA compliant laboratory test developed by Phoenix-based Provista Life Sciences. The test analyzes blood for changes in multiple serum-based protein biomarkers levels that are associated with the underlying pathology of breast cancer. The individual test results, along with a brief patient-specific medical profile, are processed through a proprietary data analysis procedure to generate a single numeric value called the BT Score, which is indicative of the presence or absence of breast cancer.
"The BT Test was designed to provide healthcare providers with another 'tool in their toolbox' that can be used as a complement with current imaging technologies in the fight to detect this devastating disease as early as possible," said William J. Gartner, CEO and President of Provista. "For Dr. Sweeten's patient, the BT Test played a role in detecting her breast cancer and we are proud of that."
The BT Test is currently available in 41 states, 27 of which are considered direct-to-consumer states where a physician's prescription is not required. The BT Test can be ordered through a women's primary healthcare provider or online. Once the sample is collected and tested, the results are sent to the patient and/or their designated primary care physician. A complete list of local Phoenix area providers is also available on the Provista Web site: www.provistals.com. To find out more about the BT Test and how it can be ordered visit their Web site or call 602-224-5500
About Provista Life Sciences
Provista Life Sciences is a biotechnology diagnostic development and commercialization organization that provides the scientific and operating management resources to rapidly advance the development and introduction of novel diagnostic technologies into the domestic and global marketplace. For more information, visit the company's Web site at www.ProvistaLS.com or call 602-224-5500
Dr. Keri Sweeten, M.D. - Understanding Women
Dr. Sweeten founded "Understanding Women" in 2003, a practice dedicated to giving women a single place to receive their most sensitive and critical healthcare needs in an understanding and caring environment. Dr. Sweeten is a board-certified gynecologist, a Fellow of the American College of Obstetricians and Gynecologists, Vice President of the Phoenix OB/Gyn Society, a member of the Society of Laparoendoscopic Surgeons, the American Academy of Cosmetic Surgeons, American Society of Lasers in Medicine and Surgery and the American Urogynecologic Society. For more information, visit her website at www.drsweeten.com or call 602-393-0661.
MEDIA CONTACTS:
The Lavidge Company
480.998.2600
Greg Sexton ext. 555
gsexton@lavidge.com
Anne Robertson ext. 537
arobertson@lavidge.com
SOURCE Provista
|
Copyright © 2008
PR Newswire. All rights reserved.
|
|
|
|
|
Related
News
Concho Resources Inc. Acquires Permian Basin Properties MIDLAND, Texas -
Concho Resources Inc. (NYSE: CXO) (“Concho” or the “Company”) today
announced that it has entered into a definitive agreement with multiple
private sellers to acquire interests in certain producing and
non-producing assets in the Wolfberry trend in th
Communications Coach Jean T. Brown: Critical First Impressions When Onboarding a New Executive
Jean T. Brown, partner with MacKenzie Brown, advises, "When onboarding a new executive, the announcement sets the tone, and can contribute to the employee's success at a significant level." Brown was interviewed for an "Inside Recruiting Onboarding Experts Series" on Tota...
New and Improved Wisconsin Cheese Cupid Makes Love with Cheese
Enhanced cheese pairing resource matches Wisconsin cheese with a bevy of beverages; features new blog, robust pairing engine and Facebook sharing at a href= http://www.cheesecupid.com onclick= linkClick( this.href ); target= _blank http://www.cheesecupid.com/a/I/P
PMadison, Wis. ...
TNS, Inc. Closes New Credit Facility RESTON, Va. -
TNS, Inc. (“TNS”) (NYSE: TNS) announced today that it has completed the
refinancing of its existing senior secured credit facilities.
The new senior secured credit facilities are comprised of a fully funded
$325 million six-year term loan and a $75 m
Doral Energy Corp.: Cohen Independent Research Group Issues Long Term Price Index Target Price of $1.21 MIDLAND, TEXAS -- 11/23/09 --
Doral Energy Corp. (OTCBB: DRLY) ("Doral" or "the Company"), announced today that Cohen Independent Research Group, Inc., Wall Street's leading independent fundamental research firm, has issued a research report on Dor..
Broadjam.com Announces Audio Mastering Service
Broadjam.com, a leading online service provider for musicians and fans, is introducing Broadjam Mastering Services to provide top-quality mastering services performed or supervised by award-winning mastering engineer Craig Anderton./I/P
PMadison, WI (PRWEB) November 23, 2009 -- Broadjam...
CF Stockholder Support for Agrium/CF Combination Significantly Greater Than Terra Stockholder Support for CF/Terra Combination CALGARY, ALBERTA -- 11/23/09 --
ALL AMOUNTS ARE STATED IN U.S.$
Agrium Inc. (TSX: AGU)(NYSE: AGU) today reiterated its appreciation for the strong support it received from the stockholders of CF Industries Holdings, Inc. (NYSE: CF) for Ag..
|
|
|
|
|
|
|
|
|